Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Outcomes of patients with light-chain amyloidosis after heart transplantation: A single center cohort.

Jose Miguel Mateos Perez, Carlos Fernandez de Larrea, José Tomás Ortiz, Luis Fernando Quintana, Joaquim Casals, Adriana Patricia Garcia, Natalia Tovar, Luis Gerardo Rodríguez-Lobato, David Moreno, Aina Oliver-Caldes, Alberto Lazaro García, Marta Farrero, Joan Batista Blade Creixenti, Laura Rosiñol Dachs, Maria Teresa Cibeira López

Blood (2025) 146 (Supplement 1): 7494.

https://doi.org/10.1182/blood-2025-7494

Published: 2025

Journal Articles

Caramel: Dual-targeting (CD123/CD33) CAR-T cell as a bridge to allogeneic transplantation for Relapsed/Refractory Acute Myeloid Leukemia. preclinical Results.

Blood (2025) 146 (Supplement 1): 7624.

https://doi.org/10.1182/blood-2025-7624

Published: 2025

Journal Articles

Multi-omic analysis reveals metabolic fitness of the ARI0002h BCMA CAR T-cell infusion product as a key predictor of clinical outcomes in multiple myeloma

Joan Mañé Pujol, Anna de Daniel, David Moreno, Clara Bueno, Laura Díaz Codony, Aina Oliver-Caldes, Oriol Cardus, Sergi Vaqué Salsench, Natalia Tovar, Helena Llobregat, Marta Español-Rego, Theo Gremen Oliveira, E. Azucena González-Navarro, Manel Juan, Luis Gerardo Rodríguez-Lobato, Anthony Battram, Carlos Fernandez de Larrea

Blood (2025) 146 (Supplement 1): 2294.

https://doi.org/10.1182/blood-2025-2294

Published: 2025

Journal Articles

Is functional cure possible in follicular lymphoma? analysis and development of a predictive model for long-term progression-free (PFS15) patients

Andrea Rivero, Monica Molina, Laura Julià, Víctor Navarro Garces, Juan Correa, Helena Brillembourg, Eduardo Aguilar-Meseguer, Carmen Rodríguez-Miñón, Isabel Hernández, Amanda Perez, Nuria Martinez-Cibrian, Valentin Ortiz-Maldonado, Nil Albiol, Aina Oliver-Caldes, Julio Delgado Gonzalez, Eva Gine, Pablo Mozas, Armando Lopez-Guillermo, Laura Magnano

Blood (2025) 146 (Supplement 1): 5386.

https://doi.org/10.1182/blood-2025-5386

Published: 2025

Journal Articles

Isotype-specific heavy/light chain quantification identifies prognostic biomarkers after ARI0002h BCMA-directed CAR-T cell therapy in multiple myeloma

Blood (2025) 146 (Supplement 1): 3983.

https://doi.org/10.1182/blood-2025-3983

Published: 2025

Journal Articles

The point-of-care network with the BCMA-directed CART ARI0002h (Cesnicabtagene Autoleucel) in patients with relapsed/refractory multiple myeloma maintains efficacy and safety in real-world data

Blood (2025) 146 (Supplement 1): 135.

https://doi.org/10.1182/blood-2025-135

Published: 2025

Journal Articles

Operational cure in patients with newly diagnosed multiple myeloma after autologous stem cell transplantation: Long-term survivors and impact of induction regimens.

Jose Miguel Mateos Perez, Francesc Fernández-Avilés, Maria Teresa Cibeira López, Maria Carmen Martinez Munoz, Carlos Fernandez de Larrea, Natalia Tovar, Luis Gerardo Rodríguez-Lobato, Maria Suarez-Lledo, Maria Queralt Salas Gay, David Moreno, Aina Oliver-Caldes, Alberto Lazaro García, Montserrat Rovira, Joan Batista Blade Creixenti, Laura Rosiñol Dachs

Blood (2025) 146 (Supplement 1): 5776.

https://doi.org/10.1182/blood-2025-5776

Published: 2025

Journal Articles

Expanding the boundaries of CAR T-cell therapy: Implementation of an outpatient-at-home (OATH) model

Blood (2025) 146 (Supplement 1): 6192.

https://doi.org/10.1182/blood-2025-6192

Published: 2025

Journal Articles

Enhanced Antitumoral Efficacy of ARI0002h CAR-T with CD28-TMD in Normal and Low BCMA Expressing Myeloma Cells

Luis Gerardo Rodríguez-Lobato, Oriol Cardus, Joan Mañé Pujol, Anthony Battram, David F. Moreno, Lorena Perez-Amill, Beatriz Martín-Antonio, Aina Oliver-Caldés, Anna De Daniel, Natalia Tovar, M Teresa Cibeira López, Laura Rosinol Dachs, Manel Juan, Alvaro Urbano-Ispizua, Carlos Fernández de Larrea

Blood (2024) 144 (Supplement 1): 359.

https://doi.org/10.1182/blood-2024-200123

Published: 2024

Journal Articles

Cilta-Cel Is Associated with Improved Outcomes and Distinct Cellular Dynamics Compared with Ide-Cel for Relapsed or Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 2003.

https://doi.org/10.1182/blood-2024-211410

Published: 2024

Journal Articles

Avatrombopag Use in Patients with Persistent Thrombocytopenia Secondary to Intensive Chemotherapy Treatment

Aser Alonso Carballo, Marta Lopez Lopez-Cepero, Maria Jimenez Moya, Sandra Pérez, Lucia García Mañó, Jose Maria Sanchez Raga, Aina Oliver Caldes, Leyre Bento De Miguel, Andres Novo Garcia, Guiomar Puget Juan, Bernat Galmes Sureda, Antonio Palomero Massanet, Carlos Fernández de Larrea, Antonia Sampol Mayol, Mariana Canaro Hinryk

Blood (2024) 144 (Supplement 1): 5445.

https://doi.org/10.1182/blood-2024-210402

Published: 2024

Journal Articles

Sequential Scmultiomics of In Vivo CAR-T Cells Allows Characterization of Transcriptional Differences between Patients, and Identifies IL10 As a Potential Mechanism of Resistance to CAR-T Cells in MM

Blood (2023) 142 (Supplement 1): 3433.

https://doi.org/10.1182/blood-2023-182887

Published: 2023

Journal Articles

ARI0002h (Cesnicabtagene Autoleucel), an Academic Point-of-Care B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Strategy: Activity and Safety after Fractionated Initial Therapy and Booster Dose in 60 Patients with Relapsed/Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 1026.

https://doi.org/10.1182/blood-2023-180828

Published: 2023

Journal Articles

Impact of Salvage and Bridging Therapy in Adult Patients with Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL) Referred for Anti-CD19 CAR T-Cell Therapy: An Intention to Treat Analysis

Blood (2023) 142 (Supplement 1): 4875.

https://doi.org/10.1182/blood-2023-187226

Published: 2023

Journal Articles

Longitudinal Transcriptomic Analysis of CAR-T Cells at Single-Cell Level Allows the Identification of Molecular Mechanisms Promoting Long-Term CAR-T Cell Persistence in MM

Blood (2023) 142 (Supplement 1): 2069.

https://doi.org/10.1182/blood-2023-182933

Published: 2023

Journal Articles

CD155 on Multiple Myeloma Cells Is Epigenetically Regulated, Reduce Patients Survival and Compromises the Action of Novel Immunotherapies

Laura Martinez-Verbo, Lorea Villanueva, Pere Llinàs-Arias, Carlos Antonio García-Prieto, David Piñeyro, Aina Oliver-Caldes, Almudena García-Ortiz, Antonio Valeri, Carlos Fernández de Larrea, Joaquin Martinez-Lopez, Gerardo Ferrer, Manel Esteller

Blood (2023) 142 (Supplement 1): 6567.

https://doi.org/10.1182/blood-2023-179313

Published: 2023

Journal Articles

CAR-T Related Cytopenia Profile in Relapsed/Refractory Multiple Myeloma: Results of Patients Treated with ARI0002h, an Academic BCMA-Directed CAR-T Cell

Blood (2022) 140 (Supplement 1): 10347–10349.

https://doi.org/10.1182/blood-2022-166525

Published: 2022

Journal Articles

Bicistronic CAR T Cell Against CD229 and BCMA Effectively Controls Multiple Myeloma

Blood (2022) 140 (Supplement 1): 10281–10282.

https://doi.org/10.1182/blood-2022-166764

Published: 2022

Journal Articles

Genetic Disruption of Blimp-1 Drastically Augments the Persistence and Anti-Tumour Efficacy of BCMA-Targeting CAR-T Cells

Anthony M Battram, Aina Oliver-Caldes, Miquel Bosch i Crespo, Oriol Cardus, David F. Moreno, Luis Gerardo Rodríguez-Lobato, Alvaro Urbano-Ispizua, Carlos Fernandez de Larrea

Blood (2022) 140 (Supplement 1): 2360–2361.

https://doi.org/10.1182/blood-2022-162399

Published: 2022

Journal Articles

Evolving Pattern Improves the IMWG 2/20/20 Classification for Patients with Smoldering Multiple Myeloma

Luis Gerardo Rodríguez-Lobato, Anna de Daniel i Bisbe, Natalia Tovar, Raquel Jiménez-Segura, M. Teresa Cibeira, David F. Moreno, Aina Oliver-Caldes, Alexandra Martínez-Roca, Ester Lozano, Joan Bladé Creixenti, Laura Rosinol Dachs, Carlos Fernandez de Larrea

Blood (2022) 140 (Supplement 1): 4341–4342.

https://doi.org/10.1182/blood-2022-165371

Published: 2022

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Outcomes of patients with light-chain amyloidosis after heart transplantation: A single center cohort.

Caramel: Dual-targeting (CD123/CD33) CAR-T cell as a bridge to allogeneic transplantation for Relapsed/Refractory Acute Myeloid Leukemia. preclinical Results.

Multi-omic analysis reveals metabolic fitness of the ARI0002h BCMA CAR T-cell infusion product as a key predictor of clinical outcomes in multiple myeloma

Is functional cure possible in follicular lymphoma? analysis and development of a predictive model for long-term progression-free (PFS15) patients

Isotype-specific heavy/light chain quantification identifies prognostic biomarkers after ARI0002h BCMA-directed CAR-T cell therapy in multiple myeloma

The point-of-care network with the BCMA-directed CART ARI0002h (Cesnicabtagene Autoleucel) in patients with relapsed/refractory multiple myeloma maintains efficacy and safety in real-world data

Operational cure in patients with newly diagnosed multiple myeloma after autologous stem cell transplantation: Long-term survivors and impact of induction regimens.

Expanding the boundaries of CAR T-cell therapy: Implementation of an outpatient-at-home (OATH) model

Enhanced Antitumoral Efficacy of ARI0002h CAR-T with CD28-TMD in Normal and Low BCMA Expressing Myeloma Cells

Cilta-Cel Is Associated with Improved Outcomes and Distinct Cellular Dynamics Compared with Ide-Cel for Relapsed or Refractory Multiple Myeloma

Avatrombopag Use in Patients with Persistent Thrombocytopenia Secondary to Intensive Chemotherapy Treatment

Sequential Scmultiomics of In Vivo CAR-T Cells Allows Characterization of Transcriptional Differences between Patients, and Identifies IL10 As a Potential Mechanism of Resistance to CAR-T Cells in MM

ARI0002h (Cesnicabtagene Autoleucel), an Academic Point-of-Care B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Strategy: Activity and Safety after Fractionated Initial Therapy and Booster Dose in 60 Patients with Relapsed/Refractory Multiple Myeloma

Impact of Salvage and Bridging Therapy in Adult Patients with Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL) Referred for Anti-CD19 CAR T-Cell Therapy: An Intention to Treat Analysis

Longitudinal Transcriptomic Analysis of CAR-T Cells at Single-Cell Level Allows the Identification of Molecular Mechanisms Promoting Long-Term CAR-T Cell Persistence in MM

CD155 on Multiple Myeloma Cells Is Epigenetically Regulated, Reduce Patients Survival and Compromises the Action of Novel Immunotherapies

CAR-T Related Cytopenia Profile in Relapsed/Refractory Multiple Myeloma: Results of Patients Treated with ARI0002h, an Academic BCMA-Directed CAR-T Cell

Bicistronic CAR T Cell Against CD229 and BCMA Effectively Controls Multiple Myeloma

Genetic Disruption of Blimp-1 Drastically Augments the Persistence and Anti-Tumour Efficacy of BCMA-Targeting CAR-T Cells

Evolving Pattern Improves the IMWG 2/20/20 Classification for Patients with Smoldering Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only